Research Article
Superficial Morphea: Clinicopathological Characteristics and a Novel Therapeutic Outcome to Excimer Light Therapy
Table 2
Therapeutic modalities and follow-up of 28 patients with superficial morphea.
| | Treatment modality | Topical therapy (potent steroid) (n = 28) | Topical combination therapy (steroid + tacrolimus) (n = 26) | Phototherapy (UVA1) (n = 20) | Phototherapy (excimer light) (n = 19) |
| | Duration | | | | | | Range (w) | 4–6 | 4–8 | 12–24 | 12–24 | | Mean ± SD | 5 ± 0.21 | 6 ± 0.73 | 18 ± 1.56 | 17 ± 2.8 |
| | Response | | | | | | Poor | 20 (71.4%) | 15 (57.7%) | 17 (85%) | 3 (15.8%) | | Good | 8 | 10 | 3 | 14 | | Excellent | 0 | 1 | 0 | 2 |
| | Flare-up/relapse | | | | | | Number | 6/8 | 5/11 | 2/3 | 1/16 | | Duration (m) | 4–7 | 1–4 | — | — |
| | Final satisfied response | 2/28 (7.1%) | 6/26 (23.1%) | 1/20 (5%) | 15/19 (78.9%) |
|
|
